Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Lease Liability Payments - 2021

Lease Liability Payments - 2021 at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$394K—

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's lease liability payments - 2021.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's lease liability payments - 2021?
Aurinia Pharmaceuticals (AUPH) reported lease liability payments - 2021 of $18.11M in Q1 2026.
How has Aurinia Pharmaceuticals's lease liability payments - 2021 changed year-over-year?
Aurinia Pharmaceuticals's lease liability payments - 2021 increased by 10.1% year-over-year, from $16.46M to $18.11M.
What does lease liability payments - 2021 mean?
This metric captures the total contractual cash payments due for operating and finance leases specifically during the 2021 fiscal period. It serves as a historical or forward-looking benchmark for lease-related cash outflows. It is used by analysts to model the company's fixed cost structure and cash flow requirements.